Necrotizing fasciitis, gas gangrene, myositis and myonecrosis

Infectious Diseases: Third Edition

Volumn 1, Issue , 2010, Pages 119-127

  Stevens, Dennis L ^a   Aldape, Michael J ^a,b   Bryant, Amy E ^a,c  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF IDAHO   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84962331107     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04579-7.00010-1     Document Type: Chapter

References (63)

1. Smith L.D.S. Clostridial wound infections. The pathogenic anaerobic bacteria 1975, 321-324. CC Thomas, Springfield, Illinois. L.D.S. Smith (Ed.).
2. Soft tissue infections among injection drug users - San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep 2001, 50:381-384. Centers for Disease Control.
3. Update: Clostridium novyi and unexplained illness among injecting-drug users - Scotland, Ireland, England, April-June 2000. MMWR Morb Mortal Wkly Rep 2000, 49:543-545. Centers for Disease Control.
4. Weinstein L., Barza M. Gas gangrene. N Engl J Med 1972, 289:1129.
5. Stevens D.L. Clostridial myonecrosis and other clostridial diseases. Cecil textbook of medicine 1996, 2090-2093. WB Saunders, Philadelphia. 20th ed. J.C. Bennett, F. Plum (Eds.).
6. Schwartz B., Facklam R.R., Brieman R.F. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990, 336:1167-1171.
7. Meleney F.L. Hemolytic streptococcus gangrene. Arch Surg 1924, 9:317-364.
8. Stevens D.L., Tanner M.H., Winship J., et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med 1989, 321:1-7.
9. Vibrio vulnificus infections associated with eating raw oysters - Los Angeles, 1996. MMWR Morb Mortal Wkly Rep 1996, 45:621-624. Anonymous.
10. Gozal D., Ziser A., Shupak A., Ariel A., Melamed Y. Necrotizing fasciitis. Arch Surg 1986, 121:233-235.
11. Stevens D.L. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome?. Clin Infect Dis 1995, 21:977-980.
12. Stevens D. Streptococcal toxic shock syndrome: spectrum of disease, pathogenesis and new concepts in treatment. Emerg Infect Dis 1995, 1:69-78.
13. Marrack P., Kappler J.W. The staphylococcal enterotoxins and their relatives. Science 1990, 248:705-711.
14. Hackett S.P., Stevens D.L. Superantigens associated with staphylococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor beta synthesis. J Infect Dis 1993, 168:232-235.
15. Stevens D.L., Bryant A.E., Hackett S.P., et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996, 173:619-626.
16. Chelson J., Halstensen A., Haga T., Hoiby E.A. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994, 344:1111-1115.
17. Hauser A.R., Stevens D.L., Kaplan E.L., Schlievert P.M. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991, 29:1562-1567.
18. Bisno A.L., Stevens D.L. Streptococcal infections in skin and soft tissues. N Engl J Med 1996, 334:240-245.
19. Stevens D.L., Gibbons A.E., Bergstrom R., Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
20. Stevens D.L., Yan S., Bryant A.E. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401-1405.
21. Stevens D.L., Bryant A.E., Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrobial Agents 1994, 4:297-301.
22. Barry W., Hudgins L., Donta S., Pesanti E. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315-3316.
23. Yong J.M. Letter. Lancet 1994, 343:1427.
24. Norby-Teglund A., Kaul R., Low D.E., McGeer A., Kotb M. Intravenous immunoglobulin and superantigen-neutralizing activity in streptococcal toxic shock syndrome patients [abstract] 1995.
25. Kaul R., McGeer A., Norby-Teglund A., Kotb M., Low D. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome: results of a matched case-controlled study [abstract LM68:339] 1995.
26. MacLennan J.D. The histotoxic clostridial infections of man. Bacteriol Rev 1962, 26:177-276.
27. Stevens D.L., Laposky L.L., Montgomery P., Harris I. Recurrent gas gangrene at a site of remote injury: localization due to circulating antitoxin. West J Med 1988, 148:204-205.
28. McNee J.W., Dunn J.S. The method of spread of gas gangrene into living muscle. Br Med J 1917, 1:727-729.
29. Robb-Smith A.H.T. Tissue changes induced by C. welchii type a filtrates. Lancet 1945, 2:362-368.
30. Bryant A.E., Bergstrom R., Zimmerman G.A., et al. Clostridium perfringens invasiveness is enhanced by effects of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity and expression of CD11/CD18 adherence-glycoprotein. FEMS Immunol Med Microbiol 1993, 7:321-326.
31. Stevens D.L., Troyer B.E., Merrick D.T., Mitten J.E., Olson R.D. Lethal effects and cardiovascular effects of purified alpha- and theta-toxins from Clostridium perfringens. J Infect Dis 1988, 157:272-279.
32. Asmuth D.A., Olson R.D., Hackett S.P., et al. Effects of Clostridium perfringens recombinant and crude phospholipase C and theta toxins on rabbit hemodynamic parameters. J Infect Dis 1995, 172:1317-1323.
33. Bryant A.E., Chen R.Y.Z., Nagata Y., et al. Clostridial gas gangrene I: cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of C. perfringens. J Infect Dis 2000, 182(3):799-807.
34. Bryant A.E., Chen R.Y.Z., Nagata Y., et al. Clostridial gas gangrene II: phospholipase C-induced activation of platelet GPIIb/IIIa mediates vascular occlusion and myonecrosis in C. perfringens gas gangrene. J Infect Dis 2000, 182(3):808-815.
35. Whatley R.E., Zimmerman G.A., Stevens D.L., Parker C.J., McIntyre T.M., Prescott S.M. The regulation of platelet activating factor synthesis in endothelial cells - the role of calcium and protein kinase C. J Biol Chem 1989, 11:6325-6333.
36. Hart G.B., Lamb R.C., Strauss M.B. Gas gangrene: I. A collective review. J Trauma 1983, 23:991-1000.
37. Terebelo H.R., McCue R.L., Lenneville M.S. Implication of plasma free hemoglobin in massive clostridial hemolysis. JAMA 1982, 248:2028-2029.
38. Gorbach S.L., Thadepalli H. Isolation of Clostridium in human infections: evaluation of 114 cases. J Infect Dis 1975, 131:S8-S85.
39. Brook I. Anaerobic bacterial bacteremia: 12-year experience in two military hospitals. J Infect Dis 1989, 160:1071-1075.
40. Butler H.M. Pathogenicity of washed Cl. welchii and mode of development of Cl. welchii infections in man. Med J Aust 1943, 2:224-226.
41. Keppie J., Robertson M. The in vitro toxigenicity and other characters of strains of Cl. welchii type A from various sources. J Pathol Bacteriol 1944, 56:123-126.
42. Stevens D.L. Clostridial infections. Atlas of infectious diseases 1995, 13.1-13.9. Churchill Livingstone, Philadelphia. D.L. Stevens, G.L. Mandell (Eds.).
43. Gorbach S.L. Clostridium perfringens and other clostridia. Infectious diseases 1992, 1587-1596. WB Saunders, Philadelphia. S.L. Gorbach, J.G. Bartlett, N.R. Blacklow (Eds.).
44. Bartlett J.G. Gas gangrene (other Clostridium-associated diseases). Principles and practice of infectious diseases 1990, 1851-1860. Churchill Livingstone, New York. G.L. Mandell, R.G. Douglas, J.E. Bennett (Eds.).
45. Stevens D.L., Maier K.A., Laine B.M., Mitten J.E. Comparison of clindamycin, rifampin, tetracycline, metronidazole and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987, 155:220-228.
46. Stevens D.L., Laine B.M., Mitten J.E. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:312-316.
47. Altemeier W.A., Fullen W.D. Prevention and treatment of gas gangrene. JAMA 1971, 217:806-813.
48. Stevens D.L., Maier K.A., Mitten J.E. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:213-218.
49. Heimbach R.D., Boerema I., Brummelkamp W.H., Wolfe W.G. Current therapy of gas gangrene. Hyperbaric oxygen therapy 1977, 153-176. Undersea Medical Society, Bethesda, MD. J.C. Davis, T.K. Hunt (Eds.).
50. Bakker D.J. Clostridial myonecrosis. Problem wounds: the role of oxygen 1988, 153-172. Elsevier, New York. J.C. Davis, T.K. Hunt (Eds.).
51. Hill G.B., Osterhout S. Experimental effects of hyperbaric oxygen on selected clostridial species: II. In vivo studies on mice. J Infect Dis 1972, 125:26-35.
52. Stevens D.L., Bryant A.E., Adams K., Mader J.T. Evaluation of hyperbaric oxygen therapy for treatment of experimental Clostridium perfringens infection. Clin Infect Dis 1993, 17:231-237.
53. Hill G.B., Osterhout S. Experimental effects of hyperbaric oxygen on selected clostridial species: I. In vitro studies. J Infect Dis 1972, 125:17-25.
54. van Unnik A.J.M. Inhibition of toxin production in Clostridium perfringens in vitro by hyperbaric oxygen. Antonie Van Leeuwenhoek 1965, 31:181-186.
55. Stevens D.L., Musher D.M., Watson D.A., et al. Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis 1990, 12:286-296.
56. Johnson S., Driks M.R., Tweten R.K., et al. Clinical courses of seven survivors of Clostridium septicum infection and their immunologic responses to a toxin. Clin Infect Dis 1994, 19:761-764.
57. Alpern R.J., Dowell V.R. Clostridium septicum infections and malignancy. JAMA 1969, 209:385-388.
58. Ballard J., Bryant A., Stevens D., Tweten R.K. Purification and characterization of the lethal toxin (alpha-toxin) of Clostridium septicum. Infect Immun 1992, 60:784-790.
59. McGregor J.A., Soper D.E., Lovell G., Todd J.K. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol 1989, 161:987-995.
60. Aldape M.J., Bryant A.E., Stevens D.L. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006, 43(11):1436-1446.
61. Aldape M.J., Bryant A.E., Ma Y., Stevens D.L. The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation. J Infect Dis 2007, 195(12):1838-1845.
62. Pannaraj P.S., Hulten K.G., Gonzalez B.E., Mason E.O., Kaplan S.L. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006, 43(8):953-960.
63. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 341:1481-1490.